These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 3358893)

  • 1. Adverse reactions to the non-drug constituents of nebuliser solutions.
    Beasley R; Rafferty P; Holgate ST
    Br J Clin Pharmacol; 1988 Mar; 25(3):283-7. PubMed ID: 3358893
    [No Abstract]   [Full Text] [Related]  

  • 2. A non-bronchoconstrictor, bacteriostatic preservative for nebuliser solutions.
    Summers QA; Nesbit MR; Levin R; Holgate ST
    Br J Clin Pharmacol; 1991 Feb; 31(2):204-6. PubMed ID: 2049239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbial contamination of nebulization solution and its measures.
    Oie S; Makieda D; Ishida S; Okano Y; Kamiya A
    Biol Pharm Bull; 2006 Mar; 29(3):503-7. PubMed ID: 16508154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution.
    Beasley CR; Rafferty P; Holgate ST
    Br Med J (Clin Res Ed); 1987 May; 294(6581):1197-8. PubMed ID: 2954609
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of preservative on the efficacy of terbutaline nebuliser solution in atopic asthma.
    Lai CK; Chan CH
    Thorax; 1993 May; 48(5):566-8. PubMed ID: 8322247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal injections--a review of pharmaceutical factors.
    Cradock JC; Kleinman LM; Davignon JP
    Bull Parenter Drug Assoc; 1977; 31(5):237-47. PubMed ID: 21718
    [No Abstract]   [Full Text] [Related]  

  • 7. [Preservatives in nebulizer solutions: risks without benefit].
    Hanquin JM
    J Pharm Belg; 1999; 54(2):38-43. PubMed ID: 10380409
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of the efficacy of preservative free ipratropium bromide and Atrovent nebuliser solution.
    Rafferty P; Beasley R; Holgate ST
    Thorax; 1988 Jun; 43(6):446-50. PubMed ID: 2971274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs.
    Pediatrics; 1997 Feb; 99(2):268-78. PubMed ID: 9024461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation and in vitro evaluation of cysteamine hydrochloride viscous solutions for the treatment of corneal cystinosis.
    Bozdağ S; Gümüş K; Gümüş O; Unlü N
    Eur J Pharm Biopharm; 2008 Sep; 70(1):260-9. PubMed ID: 18590953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are excipients really inert ingredients? A review of adverse reactions to excipients in oral dermatologic medications in Canada.
    Noiles K; Vender R
    J Cutan Med Surg; 2010; 14(3):105-14. PubMed ID: 20487670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Call for worldwide withdrawal of benzalkonium chloride from nebulizer solutions.
    Beasley R; Burgess C; Holt S
    J Allergy Clin Immunol; 2001 Feb; 107(2):222-3. PubMed ID: 11174185
    [No Abstract]   [Full Text] [Related]  

  • 13. Preservatives in nebulizer solutions: risks without benefit.
    Beasley R; Fishwick D; Miles JF; Hendeles L
    Pharmacotherapy; 1998; 18(1):130-9. PubMed ID: 9469687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability of fortified cefazolin ophthalmic solutions prepared in artificial tears containing surfactant-based versus oxidant-based preservatives.
    Rojanarata T; Tankul J; Woranaipinich C; Potawanich P; Plianwong S; Sakulma S; Saehuan C
    J Ocul Pharmacol Ther; 2010 Oct; 26(5):485-90. PubMed ID: 20879806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artificial tear issues.
    Sibley M
    Adv Exp Med Biol; 1994; 350():437-40. PubMed ID: 8030515
    [No Abstract]   [Full Text] [Related]  

  • 16. Problems presented by components of drug vehicles.
    Rogers ML; Barrett CW
    J Hum Nutr; 1976 Feb; 30(1):41-5. PubMed ID: 1026771
    [No Abstract]   [Full Text] [Related]  

  • 17. Osmolality changes in nebulizer solutions.
    Schöni MH; Kraemer R
    Eur Respir J; 1989 Oct; 2(9):887-92. PubMed ID: 2572453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Allergic reactions to local anesthetics].
    Bellver J; de Andrés JA; Bolinches R
    Rev Esp Anestesiol Reanim; 1991; 38(2):128-9. PubMed ID: 1876738
    [No Abstract]   [Full Text] [Related]  

  • 19. Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under in-use Conditions with Different Administration Materials.
    Mueller C; Dietel E; Heynen SR; Nalenz H; Goldbach P; Mahler HC; Schmidt J; Grauschopf U; Schoenhamnmer K
    Int J Pharm Compd; 2015; 19(3):261-7. PubMed ID: 26714367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simple technique to reduce preservative/excipient related neurotoxicity of intrathecal (spinal) drugs.
    Munir MA; Krishnan S; Ahmad M
    Anesth Analg; 2000 Mar; 90(3):767-8. PubMed ID: 10702476
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.